Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
Exp Biol Med (Maywood). 2010 Jan;235(1):3-9. doi: 10.1258/ebm.2009.009191.
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
肺癌（LC）是全球范围内主要的致死病因。化疗药物的最新进展并未显著改善 LC 患者的预后。所有合并疾病阶段的五年生存率仍保持在约 15%。因此，在这群患者中，诸如抑制肿瘤血管生成或阻断生长因子受体活性的新疗法特别受到关注。在本综述中，我们将总结 LC 中抑制肿瘤血管生成的生物疗法的最新临床数据，重点关注那些最具临床相关性的药物。
